Bigfoot Unity

2022: Product Launch

In early December 2022, California-based medical technology company Bigfoot Biomedical launched the Bigfoot Unity device

for patients diabetes with multiple daily injections. The system uses data continuous glucose monitoring and physician recommendations to provide insulin dose recommendations, helping patients avoid uncertainty.

Patients with type 2 diabetes are historically underserved by the medical technology industry, the developers said, in part because such patients tend to be older at diagnosis and may be less likely to adopt new technologies. This contrasts with "powerful users" of type 1 who are more aware of the nuances of their disease at an early age and are more likely to adopt new technologies to help manage it. Bigfoot Biomedical aims to offer technological solutions that will help such patients manage their disease more effectively.

Bigfoot Unity

For the first time, the Bigfoot Unity system allows people on Multiple Daily Injection (MDI) therapy to receive on-demand insulin dose recommendations based on continuous glucose monitoring (CGM) data and physician guidance, which helps eliminate alarming guesses in daily insulin dose management.

The dose in Bigfoot Unity, based on health care provider instructions, is displayed directly on patented, plug-in smart caps of disposable insulin pen syringes. The system is equipped with smart pen caps compatible with a complete list of commercially available disposable long-acting and fast insulin insulin syringes. Pen caps easily integrate with CGM's Freestyle Libre 2 sensor, providing current glucose information and insulin dosage recommendations.

CGM and dosage data are automatically uploaded to Bigfoot Clinic Hub - a secure cloud-based center that allows healthcare professionals to view health data and provide proactive, personalized care for their patients. If you combine these components, you get a comprehensive solution that is easy to understand and follow for people with diabetes.

Bigfoot Unity makes real-time insulin dose recommendations based on current CGM indications and doctor's directions. This eliminates disturbing guesses from daily insulin management. It also provides reminders of potentially missed doses of long-acting insulin to make users more likely to never miss a dose and provides notifications that glucose levels are too low. This differs from the traditional approach, in which insulin doses are determined manually and the user tries to remember when he took the last dose. With Bigfoot Unity, you do not need to enter data manually.

For December 2022, Bigfoot Unity is approved FDA and available on site. USA The company's management is actively working to expand access so that more people with diabetes requiring insulin can take control of their diabetes with a comprehensive, simple and holistic solution.^[1]

2021: Insulin Pen Smart Cap Announcement to Determine Insulin Dosage

In early May 2021, the first smart cap for insulin pen syringes was released. We are talking about the Bigfoot Unity product manufactured by Bigfoot Biomedical. It helps diabetic patients determine the correct insulin dosage.

The smart cap is designed for use by patients with type one and two diabetes. Approved for use by persons aged 12 years and older, the cap supports synchronization with the glucose monitoring system FreeStyle Libre 2 from, Abbot which allows you to monitor indicators in real time. All data collected by the system is automatically stored in cloud storage when there is a signal Wi-Fi or cellular communication, tracking of all collected data is available through a mobile application.

First Bigfoot Unity Pen Syringe Smart Cap Released, It Helps Patients With Correct Insulin Dosage Calculation

Using tools on the Bigfoot Clinic Hub website, the data can also be viewed by the patient's treating physician and make adjustments to the treatment regimen. Bigfoot Unity will be available in some American clinics as early as spring 2021.

People with diabetes can be overwhelmed by the amount of data they get from multiple devices, so it's important to develop connected technologies that make things easier, "said Jared Watkin, senior vice president of Diabetes Care at Abbott. - Through Abbott's collaboration with Bigfoot Biomedical, we are integrating our revolutionary, easy-to-use FreeStyle Libre 2 technology with Bigfoot Unity to provide automated information for personalized diabetes management.

The product is compatible with all major American brands of fast and long acting disposable insulin pens, including those manufactured by Eli Lilly and Company, Novo Nordisk and Sanofi. A special sensor is attached to the patient's shoulder and records the glucose level in his body, then the recorded indicators are transmitted to the smart cap, which, in turn, makes a calculation of the insulin dose necessary for the patient, the indicator is displayed on his screen.^[2]

Notes